Objective: The aim of this study was to compare type 1 and type 2 papillary renal cell carcinoma (RCC) for validating this subclassification as a prognostic factor. Methods: A total of 70 patients with chromophobe RCC were included in the analysis. Patients with papillary RCC were categorized into type 1 (n ¼ 33) and type 2 (n ¼ 37). Results: The median progression-free survival was 31.0 months for the type 1 group and 12.0 months for the type 2 group (P ¼ 0.001). The median cancer-specific survival was 41.1 months for the type 1 group and 24.0 months for the type 2 group (P ¼ 0.097). Multivariate Cox proportional hazards model for patients with papillary RCC showed that no variables including histologic subtyping were independent predictors of progression-free and cancerspecific survival. Conclusions: In the present study, the type of papillary RCC does not reach independent prognostic significance.
INTRODUCTION
Renal cell carcinoma (RCC) is a heterogenous disease consisting of various subtypes with diverse genetic, biochemical and morphologic features. Papillary RCCs represent 10 -20% of all RCCs and are the second most frequent histologic form after clear cell RCC (1, 2) . Papillary RCCs are histologically characterized by the presence of fibrovascular cores with tumor cells arranged in a papillary configuration. The majority of papillary RCC tumors show indolent behavior and have a limited risk of progression and mortality, but a distinct subset displays highly aggressive behavior (3) . Thus, papillary RCC seems to constitute clinically, histologically and even genetically highly heterogenous groups, suggesting the necessity for characterizing their subtypes.
In 1997, Delahunt and Eble (3) found two papillary RCC histologic subtypes, type 1 and type 2. Type 1 is characterized by the presence of small cuboidal cells covering thin papillae, with a single line of small uniform nuclei and basophilic cytoplasm. Type 2 is characterized by the presence of large tumor cells with eosinophilic cytoplasm and pseudostratification. Despite the small number of studies analyzing prognosis of papillary RCC based on this morphologic classification, it has been generally accepted that type 1 papillary RCC has a more favorable survival than type 2 papillary RCC (4 -10). However, the morphologic classification remains controversial, and there is limited molecular and biochemical evidence to support this morphologic classification. The relatively high incidence of mixed type 1 and 2 tumors poses additional difficulties for such a method of classification. Furthermore, published series have shown conflicting results regarding the clinical implication of papillary RCC subtyping (11) .
In (14) . The T stage was T1 in 47, T2 in 10 and T3 in 13 patients, with Fuhrman's grade 2 in 27, grade 3 in 37 and grade 4 in 1 patient.
The patients were evaluated with office visits, laboratory workups and chest X-ray every 6 months for 5 years and yearly thereafter. Computed tomography and bone scans were performed yearly and on request until disease progression. Median follow-up duration of total patients was 29.0 months [95% confidence interval (CI), 7.6 -115.7] . Deaths were determined by reviewing medical records and/ or confirmed by interview with the patient's family.
The microscopic slides from all tumor specimens were reviewed by a urologic pathologist (K.C.M) without the knowledge of patient outcome. The histologic subtype and Fuhrman's nuclear grade were determined. The presence of tumor necrosis was evaluated based on macroscopic description of tumor, and tumors were considered necrotic only if they exhibited .10% macroscopic necrosis which would be apparent to experienced pathologists on gross examination of specimen. Lymphovascular invasion was defined as the unequivocal presence of tumor cells within the endothelial linings of lymphatic and/or vascular channels.
For statistical analysis, patients with papillary RCC were categorized into type 1 (n ¼ 33) and type 2 (n ¼ 37). The characteristics of subject groups were compared using the x 2 test. The statistical endpoint in our analysis was progressionfree and cancer-specific survival of patients. Kaplan -Meier survival curves were generated from the life table analysis, and survival was compared using log-rank tests. Prognostic implications of selected variables were evaluated using the Cox proportional hazards model. The statistical software package SPSS 13.0 (SPSS, Inc., Chicago, IL, USA) was used for all statistical analyses, with P , 0.05 indicating statistical significance.
RESULTS
Characteristics of the patient population are shown in Table 1 . Patients with type 1 papillary RCC differed significantly from those with type 2 papillary RCC for the following parameters: smaller tumor diameter (P ¼ 0.009), less advanced TNM stage (P ¼ 0.004), lower Fuhrman nuclear grade (P , 0.001), less tumor necrosis (P , 0.001) and less lymphovascular invasion (P ¼ 0.011). There was no statistical difference with regard to age and tumor diameter. During the follow-up periods, disease progression occurred in 11 patients (15.7%) with papillary RCC and 8 (11.4%) died related to their tumor disease with a median follow-up of 29.0 months. The 1-, 3-and 5-year progressionfree survival rates were calculated at 91.3%, 82.5% and 82.5%, respectively. The 1-, 3-and 5-year cancer-specific survival rates were 92.5%, 88.8% and 83.5%, respectively. The median progression-free survival was 31.0 months (95% CI, 4.0 -123.7) for the type 1 group and 12.0 months (95% CI, 0.0 -72.8) for the type 2 group, respectively (P ¼ 0.001) (Fig. 1A) . Progression-free survival rates at 1 year were 96.4% and 73.8%, at 3 year 96.4% and 62.7%, and at 5 year 87.7% and 62.7%, respectively. The median cancer-specific survival was 41.1 months (95% CI, 7.7 -143.3) for the type 1 group and 24.0 months (95% CI, 5.0 -91.0) for the type 2 group, respectively (P ¼ 0.097) (Fig. 1B) . Cancer-specific rates at 1 year were 96.6% and 89.0%, at 3 year 96.6% and 80.3%, and at 5 year 89.7% and 80.3%, respectively.
Univariate associations of the clinical and pathologic features studied with death from RCC are summarized in Table 2 . The TNM stage (P ¼ 0.005 and P ¼ 0.015), and the presence of tumor necrosis (P ¼ 0.014 and P ¼ 0.034) and lymphovascular invasion (P , 0.001 and P ¼ 0.004) were significantly associated with progression-free and cancerspecific survival for papillary RCC, respectively. Although mode of presentation (P ¼ 0.011) and histologic subtype (P ¼ 0.007) were significantly associated with progressionfree survival, there was not a statistically significant association with death from papillary RCC.
Multivariate Cox proportional hazards model analysis using the variables of mode of presentation, TNM stage, tumor necrosis, lymphovascular invasion and histologic type showed that no variables were independent predictors of progressionfree survival; additionally, using the variables including the TNM stage, necrosis and lymphovascular invasion, all variables were not independent prognostic predictors of cancerspecific survival and lost statistical significance (Table 3) .
DISCUSSION
The identification of valid histologic prognostic parameters for renal parenchymal malignancies has, to date, proved to be somewhat elusive. Although large monocentric series with expert pathologic review have been published (1, 5, (15) (16) (17) , no consensus has been reached on the independent prognostic value of histologic type. In 1999, Ljungberg et al. (18) were the first to observe significantly different cancer-specific survivals in the three main RCC histotypes. In that series, patients with papillary RCC had significantly longer survival, compared with those with clear cell RCC, as did patients with chromophobe RCC. Beck et al. (17) also reported that when multivariate analysis was performed, histologic type did retain significance when tumor stage and grade were included in the analysis. In a large series of 2528 patients from Mayo Clinic, Figure 1 . (A) Progression-free survival in patients with type 1 and type 2 papillary renal cell carcinoma (RCC) (log-rank test for trend, P ¼ 0.001). (B) Cancer-specific survival in patients with type 1 and type 2 papillary RCC (log-rank test for trend, P ¼ 0.097).
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Histologic subtypes of papillary RCC Cheville et al. (15) showed that patients with clear RCC had significantly lower cancer-specific survival probabilities, compared with those with papillary or chromophobe RCC, even after stratification by pathologic stage and nuclear grading. Also, in that series, no survival difference was observed between papillary and chromophobe RCC. However, in most series where multivariate analysis was performed, histologic type did not retain significance when tumor stage and grade were included in the analysis (1, 2, 16, 19) . In our series, type 2 papillary RCC was larger, advanced and poorer differentiated, and more frequently showed tumor necrosis and lymphovascular invasion compared with type 1 papillary RCC. However, we could not found statistically significant difference in cancer-specific survival probability, although progression-free survival rates in type 1 papillary RCC was higher than in type 2 papillary RCC. Fuhrman et al. (13) noted that nuclear grading was applicable to all tumors of any size, pattern and cell type; however, Sika-Paotonu et al. (20) suggested that this grading system was not applicable to papillary RCC. Ficarra et al. (21) reported that the 2002 TNM staging system did not appropriately stratify the cancer-related outcome of the patients with papillary RCC. In that subgroup of patients, the disease-specific survival rates of patients with pT1a tumors overlapped those reported for patients with pT1b tumors, although a close to statistical significance was found when comparing the outcome both of patients with pT1a and pT2 (P ¼ 0.05) and patients with pT1b and pT2 (P ¼ 0.06) papillary RCC. 
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Histologic subtypes of papillary RCC Table 4 summarizes the survival difference of type 1 and 2 papillary RCC in the published series (4 -11) . The poorer outcome of type 2 tumors on univariate analysis (4,5,7 -10) was also shown in a multivariate analysis of overall survival in a series by Delahunt et al. (6) and Allory et al. (8) . In series of Pignot et al. (10) , type 2 papillary RCC was an independent prognostic factor of disease-free survival. However, Yamanaka et al. (11) reported that there were no significant differences in overall and cause-specific survival. Furthermore, other series could not confirm that survival rates in type 1 papillary RCC was higher than those in type 2 papillary RCC in the multivariate analysis (5, 9) . These findings suggest that the discrepancy among reports might be a result of the small number of patients with short follow-up period. Therefore, data regarding the prognostic significance of histologic subtyping papillary RCC are limited, largely due to the small numbers of cases in most series and the apparent favorable prognosis of this tumor type, with relatively few tumorrelated deaths being reported.
Our study has several weaknesses. First of all, our study is a retrospective one and included a small number of patients with a relatively short follow-up. Delahunt et al. (22) demonstrated that the risk of death as a result of RCC is continuous for increasing size if sample sizes are large enough. Therefore, our findings will have to be validated by additional studies in a larger series.
In the present study, the type of papillary RCC did not reach independent prognostic significance in multivariate analysis, possibly due to the correlation between the histologic subtype and the histologic grade or stage. Further investigations of the clinicopathological characteristics of papillary RCC are needed to fully characterize this neoplasm of the kidney.
